OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems to search, print, or electronically dispense directly to patients, as well as for a network of pharmacies; and Brand and Clinical Messaging that includes various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages targeted by specialty, diagnostic code, and other criteria. The company's products and applications also comprise brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing new eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. It also operates Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence, care coordination, and patient engagement; and HIPAA-compliant, an automated and mobile messaging platform that allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. OptimizeRx Corporation is based in Rochester, Michigan.
Industry, Sector and Symbol
Industry Business services, not elsewhere classified
Sub-IndustryN/A
SectorComputer and Technology
CIKN/A
Phone248-651-6568
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$21.21 million
Profitability
Miscellaneous
Employees37
Next Earnings Date2/25/2020 (Estimated)
OptionableNot Optionable
OptimizeRx (NASDAQ:OPRX) Frequently Asked Questions
What is OptimizeRx's stock symbol?
OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."
How were OptimizeRx's earnings last quarter?
OptimizeRx Co. (NASDAQ:OPRX) announced its quarterly earnings results on Tuesday, November, 5th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.15. The company earned $5 million during the quarter, compared to analyst estimates of $7.21 million. OptimizeRx had a negative net margin of 5.32% and a negative return on equity of 3.68%. View OptimizeRx's Earnings History.
When is OptimizeRx's next earnings date?
What price target have analysts set for OPRX?
2 brokers have issued 12-month target prices for OptimizeRx's stock. Their forecasts range from $20.00 to $20.00. On average, they anticipate OptimizeRx's share price to reach $20.00 in the next year. This suggests a possible upside of 79.9% from the stock's current price. View Analyst Price Targets for OptimizeRx.
What is the consensus analysts' recommendation for OptimizeRx?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OptimizeRx.
Has OptimizeRx been receiving favorable news coverage?
Press coverage about OPRX stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. OptimizeRx earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for OptimizeRx.
Are investors shorting OptimizeRx?
OptimizeRx saw a decrease in short interest in January. As of January 31st, there was short interest totalling 734,200 shares, a decrease of 13.2% from the January 15th total of 845,500 shares. Based on an average trading volume of 107,800 shares, the short-interest ratio is presently 6.8 days. Currently, 6.4% of the company's stock are sold short. View OptimizeRx's Current Options Chain.
Who are some of OptimizeRx's key competitors?
Some companies that are related to OptimizeRx include Uxin (UXIN), Resources Connection (RECN), PaySign (PAYS), NEWTEK Business Services (NEWT), International Money Express (IMXI), Rimini Street (RMNI), COMSCORE (SCOR), Points International (PCOM), Collectors Universe (CLCT), 36Kr (KRKR), Gravity (GRVY), InnerWorkings (INWK), Moneygram International (MGI), Servicesource International (SREV) and China Customer Relations Centers (CCRC).
What other stocks do shareholders of OptimizeRx own?
Who are OptimizeRx's key executives?
OptimizeRx's management team includes the folowing people:
- Mr. William J. Febbo, CEO & Director (Age 50)
- Ms. Miriam J. Paramore, Pres (Age 56)
- Mr. Douglas P. Baker, Chief Financial Officer (Age 62)
- Mr. Terence J. Hamilton, Sr. VP of Sales (Age 54)
- Mr. James Brooks, Consultant (Age 50)
Who are OptimizeRx's major shareholders?
OptimizeRx's stock is owned by a number of of retail and institutional investors. Top institutional investors include P.A.W. Capital Corp (2.01%), State Street Corp (1.69%), Perkins Capital Management Inc. (1.21%), Calamos Advisors LLC (1.15%), Cadence Capital Management LLC (0.97%) and Bullseye Asset Management LLC (0.78%). Company insiders that own OptimizeRx stock include Awm Investment Company, Inc, Douglas P Baker, Ellen O'connor Vos, Gus D Halas, Miriam J Paramore, Patrick D Spangler and William J Febbo. View Institutional Ownership Trends for OptimizeRx.
Which major investors are selling OptimizeRx stock?
OPRX stock was sold by a variety of institutional investors in the last quarter, including 1492 Capital Management LLC, Calamos Advisors LLC, Russell Investments Group Ltd., THB Asset Management, Driehaus Capital Management LLC, Taylor Wealth Management Partners, Cadence Capital Management LLC and Perkins Capital Management Inc.. View Insider Buying and Selling for OptimizeRx.
Which major investors are buying OptimizeRx stock?
OPRX stock was purchased by a variety of institutional investors in the last quarter, including P.A.W. Capital Corp, Bullseye Asset Management LLC, Blair William & Co. IL, Atlantic Trust LLC, Rhumbline Advisers, Bank of America Corp DE, State Street Corp and Barclays PLC. Company insiders that have bought OptimizeRx stock in the last two years include Ellen O'connor Vos, Gus D Halas, Miriam J Paramore, Patrick D Spangler and William J Febbo. View Insider Buying and Selling for OptimizeRx.
How do I buy shares of OptimizeRx?
Shares of OPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is OptimizeRx's stock price today?
One share of OPRX stock can currently be purchased for approximately $11.12.
How big of a company is OptimizeRx?
OptimizeRx has a market capitalization of $157.57 million and generates $21.21 million in revenue each year. The company earns $230,000.00 in net income (profit) each year or $0.05 on an earnings per share basis. OptimizeRx employs 37 workers across the globe.View Additional Information About OptimizeRx.
What is OptimizeRx's official website?
How can I contact OptimizeRx?
OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The company can be reached via phone at 248-651-6568 or via email at [email protected]
MarketBeat Community Rating for OptimizeRx (NASDAQ OPRX)
MarketBeat's community ratings are surveys of what our community members think about OptimizeRx and other stocks. Vote "Outperform" if you believe OPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
